New treatments for nervous disorders

Abstract

This patent application describes the treatment of Addictive disorders, Psychoactive Substance Use disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco addiction and or Nicotine addiction; and Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.

1 . A method of treating or enhancing the treatment of a disorder selected from: 
 a) Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and    b) Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient.    
   
   
       2 . The method of  claim 1  where Reboxetine is used to treat or enhance the treatment of Tobacco and or Nicotine Addiction.  
   
   
       3 . The method of  claim 2  where Reboxetine is used to reduce the craving for Tobacco or Nicotine containing products.  
   
   
       4 . The method of  claim 2  where Reboxetine is used to reduce the smoking or chewing of Tobacco or Nicotine containing products.  
   
   
       5 . The method of  claim 1  where Reboxetine is used to treat or enhance the treatment of Attention Deficit Hyperactivity Disorder (ADHD).  
   
   
       6 . The method of  claim 5  where Reboxetine is used to increase the attention span and calm individuals afflicted with ADHD.  
   
   
       7 . A method for treating or enhancing the treatment of a disorder selected from: 
 a) Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and    b) Attention Deficit Hyperactivity Disorder (ADHD); comprising administering a therapeutically effective, nontoxic dose of Reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient in need of an effective treatment thereof.    
   
   
       8 . The use of Reboxetine or its pharmaceutically acceptable salts in the manufacture of a medicament to treat: 
 a) Addictive Disorders, Psychoactive Substance Use Disorders, Intoxication disorders, Inhalation disorders, Alcohol addiction, Tobacco Addiction and or Nicotine Addiction; and    b) Attention Deficit Hyperactivity Disorder (ADHD);    and for any of the symptoms of any of those diseases.    
   
   
       9 . The method or use in claims  1 - 8  where the reboxetine dose range is 4 to 10 mg. per patient per day.  
   
   
       10 . The method or use in claims  1 - 8  where the reboxetine dose range is 6 to 8 mg. per patient per day.